Biochemical bone turnover markers in patients with conventional and nonconventional osteosarcoma;Markery obrotu kostnego u chorych na konwencjonalna̧ i niekonwencjonalna̧ postać histologiczna̧ miȩsaka kościopochodnego

Polski Merkuriusz Lekarski

Volumn 21, Issue 124, 2006, Pages 330-334

  Ambroszkiewicz, Jadwiga ^a,b   Gajewska, Joanna ^a,b   Klepacka, Teresa ^b   Bilska, Katarzyna ^b   Woźniak, Wojciech ^b   Laskowska Klita, Teresa ^a,b  

^a INSTITUTE OF PSYCHIATRY AND NEUROLOGY   (Poland)

^b INSTITUTE OF MOTHER AND CHILD   (Poland)

Author keywords

Bone turnover markers; Children and adolescents; Conventional and nonconventional osteosarcoma

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; BIOCHEMICAL MARKER; CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN TYPE 1; OSTEOCALCIN;

ADOLESCENT; ADULT; ARTICLE; BONE TURNOVER; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DISEASE CLASSIFICATION; ENZYME IMMUNOASSAY; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; OSTEOSARCOMA; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; SCHOOL CHILD; TUMOR BIOPSY;

ADOLESCENT; ADULT; ALKALINE PHOSPHATASE; BONE NEOPLASMS; BONE REMODELING; BONE RESORPTION; CHILD; CHILD, PRESCHOOL; COLLAGEN TYPE I; FEMALE; HUMANS; MALE; OSTEOCALCIN; OSTEOSARCOMA; PEPTIDES; PROGNOSIS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 33751046310     PISSN: 14269686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Ambroszkiewicz J., Gajewska J., Laskowska-Klita T.: Kostna frakcja fosfatazy alkalicznej: charakterystyka i przydatność kliniczna. Med. Wieku Rozwoj., 2002, 2, 99-110.
2. Ambroszkiewicz J., Gajewska J., Laskowska-Klita T. i wsp.: Biochemiczne wskaźniki procesu resorpcji kości u dzieci z osteosarcoma. Med. Wieku Rozwoj., 2004, 2, 225-233.
3. Bacci G., Picci P., Orlandi M. i wsp.: Prognostic value of serum alkaline phosphatase in osteosarcoma. Tumori, 1987, 73, 331-336.
4. Berruti A., Dogliotti L., Gorzegno G. i wsp.: Differential patterns of bone turnover in relation to bone pain and disease extent in bone in cancer patients with skeletal metastases. Clin. Chem., 1999, 45, 240-1247.
5. Burlina A., Rubin D., Secchiero S. i wsp.: Monitoring skeletal cancer metastases with the bone isoenzyme of tissue unspecific alkaline phosphatase. Clin. Chim. Acta, 1994, 226, 151-158.
6. Calvo M.S., Eyre D.R., Gunberg C.M. i wsp.: Molecular basis and clinical application of biological markers of bone turnover. Endocrine Rev., 1996, 17, 333-368.
7. Coleman R.E.: Metastatic bone disease and the role of biochemical markers of bone metabolism in benign and malignant diseases. Cancer Tret. Rev., 2001, 27, 133-135.
8. Demers L.M., Costa L., Lipton A.: Biochemical markers and skeletal metastases. Cancer, 2000, 88, 2919-2926.
9. Demers L.M.: Bone markers in the management of patients with skeletal metastases. Cancer, 2003, 97, 874-879.
10. Dorfman H.D., Czerniak B.: Bone tumors. Chapter 5: Osteosarcoma ed Mosby Inc., 1998, 128-252.
11. Fanburg J.C., Rosenberg A.E., Weaver D.L. i wsp.: Osteocalcin and osteonectin immunoreactivity in the diagnosis of osteosarcoma. Am. J. Clin. Pathol., 1997, 108, 464-473.
12. Fanburg-Smith J.C., Bratthauer G.L., Miettinen M.: Osteocalcin and osteonectin immunoreactivity in extraskeletal osteosarcoma: A study of 26 cases. Human Pathol., 1999, 30, 32-38.
13. Fontana A., Delmas P.D.: Markers of bone turnover in bone metastases. Cancer, 2000, 88, 2952-2960.
14. Gajewska J., Ambroszkiewicz J., Rychłowska-Pruszynska M. i wsp.: Serum markers of bone formation in patients with osteosarcoma. Med. Fed. Oncol., 2000, 35, 319.
15. Gajewska J., Ambroszkiewicz J., Rychłowska-Pruszyńska M. i wsp.: Markery kościotworzenia u dzieci z osteosarcoma. Med. Wieku Rozwoj., 2004, 2, 235-243.
16. Hopyan S., Gokgoz N., Bell R.S. i wsp.: Expression of osteocalcin and its transcriptional regulators core-binding factor alfa 1 and MSX2 in osteoid-forming tumours. J. Orthop. Res., 1999, 17, 633-638.
17. Jung K., Lein M., Stephan C. i wsp. Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications. Int. J. Cancer, 2004, 111, 783-791.
18. Koizumi M., Yamada Y., Takiguchi T. i wsp.: Bone metabolic markers in bone metastases. J. Cancer Res. Clin. Oncol., 1995, 121, 542-548.
19. Levine A.M., Triche T., Rosenberg S.A. i wsp.: Osteosarcoma cells in tissue culture: II. Characterisation and localisation of alkaline phosphatase activity. Clin. Ortop. Related Res., 1980, 146, 259-268.
20. Liebhart M., Klepacka T., Michalak E.: Typ histologiczny miȩsaka kościopochodnego a odsetek martwicy guza po wstȩpnej chemioterapii. Med. Wieku Rozwoj., 2000, 2, supl. 2, 57-66.
21. Manara M.C., Baldini N., Serra M. i wsp.: Reversal of malignant phenotype in human osteosarcoma cells transduced with the alkaline phosphatase gene. Bone, 2000, 26, 215-220.
22. Meijer W.G., van der Veer E., Willemse P.H.: Biochemical parameters of bone metabolism in bone metastases of solid tumors. Oncology Reports, 1998, 5, 5-21.
23. Rychłowska-Pruszyńska M., Ługowska I., Gajewska J. i wsp.: Bone-specific alkaline phosphatase in serum as a prognostic factor in osteosarcoma in children. Preliminary report at Mother and Child Institute, Poland. W: Advances in Pediatric Bone Marrow Transplantation and Oncology. Wroclaw Medical University, Wrocław, 2004, 244-249.
24. Seregni E., Martinetti A., Ferrari L. i wsp.: Clinical utility of biochemical marker of bone remodeling in patients with metastases of solid tumors. Q. J. Nucl. Med., 2001, 45, 7-17.
25. Stoba C., Czauderna P.: Guzy kości u dzieci. Diagnostyka i leczenie. Folium, Lublin, 1997.
26. Van Hoof V.O., Van Osterom A.T., Lepourte L.G. i wsp.: Alkaline phosphatase isoenzyme patterns in malignant disease. Clin. Chem., 1992, 38, 2546-2551.
27. Vinholes J., Coleman R., Eastell R.: Effects of bone metastases on bone metabolism: implication for diagnosis imaging and assessment of response to cancer treatment. Cancer Treat. Rev., 1996, 22, 289-331.